Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Depreciation & Amortization (CF) (2016 - 2025)

Cardiff Oncology's Depreciation & Amortization (CF) history spans 15 years, with the latest figure at $88000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 8.33% year-over-year to $88000.0; the TTM value through Dec 2025 reached $364000.0, down 9.9%, while the annual FY2025 figure was $364000.0, 9.9% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $88000.0 at Cardiff Oncology, down from $89000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $119000.0 in Q1 2021 and bottomed at $31000.0 in Q1 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $97000.0 (2023), against an average of $92650.0.
  • The largest annual shift saw Depreciation & Amortization (CF) plummeted 73.95% in 2022 before it surged 190.32% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $113000.0 in 2021, then fell by 23.89% to $86000.0 in 2022, then rose by 19.77% to $103000.0 in 2023, then dropped by 6.8% to $96000.0 in 2024, then decreased by 8.33% to $88000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Depreciation & Amortization (CF) are $88000.0 (Q4 2025), $89000.0 (Q3 2025), and $94000.0 (Q2 2025).